CG Oncology, Inc. (CGON)
NASDAQ: CGON · Real-Time Price · USD
41.93
-0.52 (-1.22%)
At close: Jan 8, 2026, 4:00 PM EST
42.01
+0.08 (0.19%)
After-hours: Jan 8, 2026, 7:05 PM EST
CG Oncology Stock Forecast
Stock Price Forecast
The 12 analysts that cover CG Oncology stock have a consensus rating of "Strong Buy" and an average price target of $67.83, which forecasts a 61.77% increase in the stock price over the next year. The lowest target is $47 and the highest is $90.
Price Target: $67.83 (+61.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CG Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 7 | 8 | 7 | 7 |
| Buy | 5 | 6 | 6 | 6 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 13 | 14 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $70 | Buy | Initiates | $70 | +66.94% | Dec 11, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $62 | Strong Buy | Initiates | $62 | +47.87% | Nov 24, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $53 → $61 | Buy | Maintains | $53 → $61 | +45.48% | Nov 17, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $90 | Strong Buy | Initiates | $90 | +114.64% | Oct 8, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $41 → $47 | Buy | Maintains | $41 → $47 | +12.09% | Sep 26, 2025 |
Financial Forecast
Revenue This Year
1.85M
from 1.14M
Increased by 62.77%
Revenue Next Year
34.60M
from 1.85M
Increased by 1,766.40%
EPS This Year
-2.22
from -1.41
EPS Next Year
-2.67
from -2.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.4M | 116.5M | ||||
| Avg | 1.9M | 34.6M | ||||
| Low | 1.7M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 112.0% | 6,183.7% | ||||
| Avg | 62.8% | 1,766.4% | ||||
| Low | 46.3% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.22 | -1.43 | ||||
| Avg | -2.22 | -2.67 | ||||
| Low | -2.21 | -3.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.